Boston, MANCT07601425Now EnrollingIRB Ready

Hereditary Hemorrhagic Telangiectasia (HHT) Clinical Trial in Boston, MA

Access cutting-edge hereditary hemorrhagic telangiectasia (hht) treatment through this phase 1/2 clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Atavistik Bio, Inc

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access hereditary hemorrhagic telangiectasia (hht) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hereditary hemorrhagic telangiectasia (hht) treatment provided free

Apply for This Boston Location

Check if you qualify for this hereditary hemorrhagic telangiectasia (hht) clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Hereditary Hemorrhagic Telangiectasia (HHT) Study in Boston

This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601. Patients completing Part 1 may participate in the Part 2 open-label extension to receive ATV-1601.

Sponsor: Atavistik Bio, Inc

Who Can Participate

Inclusion Criteria

Ability to provide informed consent prior to any study-specific procedures
Confirmed diagnosis of hereditary hemorrhagic telangiectasia (HHT) based on Curaçao criteria
Moderate to severe HHT with an ESS ≥ 4
Anemia at Screening and/or requirement for at least 1 red-cell unit (RUE) in the previous 6 months
Adequate hematologic, renal, and hepatic function per protocol-defined laboratory criteria
Use highly effective contraception during the study and for a protocol-defined period after last dose

Exclusion Criteria

Clinically significant abnormalities of glucose metabolism including diagnosed Type 1 or uncontrolled Type 2 diabetes
Chronic cardiac disease, or cardiac rhythm abnormalities
History of significant cardiovascular, hepatic, renal, or hematologic disease not related to HHT that may confound study results
Use of prohibited concomitant medications within a protocol-defined washout period prior to first dose (including strong CYP modulators and certain herbal supplements)
Recent (within 6 weeks) major surgery or local ablative procedures, or procedures on nasal telangiectasias
Prior AKT inhibitor
Pregnant or breastfeeding women Additional Criteria for Open-Label Extension:
Participants must complete the double-blind treatment period (Part 1)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT07601425) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hereditary Hemorrhagic Telangiectasia (HHT) Treatment Options in Boston, MA

If you're searching for hereditary hemorrhagic telangiectasia (hht) treatment options in Boston, MA, this clinical trial (NCT07601425) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced hereditary hemorrhagic telangiectasia (hht) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hereditary hemorrhagic telangiectasia (hht) clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Boston, MA

See all ankylosing spondylitis clinical trials recruiting in Boston — not just this study.

Browse Ankylosing Spondylitis Trials in Boston →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA